Skip to main content
. Author manuscript; available in PMC: 2019 Mar 16.
Published in final edited form as: Clin Lung Cancer. 2018 Aug 4;19(6):e853–e859. doi: 10.1016/j.cllc.2018.07.004

Figure 1.

Figure 1

Best Percentage Change From Baseline in Sum of Diameters (SD, Longest for Non-Nodal Lesion, Short Axis for Nodal Lesion) of Target Lesions. Dose Level M1: Momelotinib 100 mg Once Daily (q.d.) With Trametinib 1.0 mg q.d.; Dose Level M2A: Momelotinib 200 mg q.d. With Trametinib 1.0 mg q.d.; Dose Level M2B: Momelotinib 100 mg Twice Daily (b.i.d.) With Trametinib 1.0 mg q.d.; Dose Level M3: Momelotinib 150 mg b.i.d. With Trametinib 1.0 mg q.d.; and Dose Level TI: Momelotinib 150 mg b.i.d. With Trametinib 1.5 mg q.d.